Antipsychotic management in primary care: a longitudinal

population-based study

- 3 Short title: Trends in antipsychotic management in primary care
- 4 Alan Woodall^{1,2}, Alex Gampel², Huw Collins^{3†}, Lauren E Walker⁴, Frances S Mair⁵, Sally
- 5 Sheard⁶, Pyers Symon⁷, Iain Buchan^{7,8*}

1

- 6 ¹Department of General Practice and Mental Health, Institute of Population Health,
- 7 University of Liverpool, Liverpool, United Kingdom.
- 8 ²Powys Teaching Health Board, Bronllys, Brecon, Powys, United Kingdom.
- 9 ³Secure Anonymised Information Linkage Databank, Data Science Building, Swansea
- 10 University, Swansea, United Kingdom
- ⁴Centre for Experimental Therapeutics, University of Liverpool, Liverpool, United Kingdom
- ⁵Department of General Practice and Primary Care, School of Health and Wellbeing,
- 13 University of Glasgow, Glasgow, United Kingdom
- 14 ⁶Department of Public Health, Policy and Systems, Institute of Population Health, University
- of Liverpool, Liverpool, United Kingdom
- ⁷NIHR Mental Health Research for Innovation Centre, University of Liverpool, Liverpool,
- 17 United Kingdom
- 18 Civic Health Innovation Labs, University of Liverpool, Liverpool, United Kingdom
- *Corresponding author: lain Buchan buchan@liverpool.ac.uk
- NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. TDeceased

ORCID IDs and emails:	
Alan Woodall: 0000-0003-2933-0508	alan.woodall@wales.nhs.uk
Alex Gampel: 0000-0001-6923-5818	alexandra.gampel@wales.nhs.uk
Huw Collins (deceased; no ORCID/email pr	rovided)
Lauren Walker: 0000-0002-3827-4387	lauren.walker@liverpool.ac.uk
Frances Mair: 0000-0001-9780-1135	frances.mair@glasgow.ac.uk
Sally Sheard: 0000-0001-8116-9120	sheard@liverpool.ac.uk
Pyers Symon: 0009-0001-6499-8442	pyers.symon@zen.co.uk (public advisor)
lain Buchan: 0000-0003-3392-1650	buchan@liverpool.ac.uk

Abbreviations

33

- 34 APM- Antipsychotic Medication
- 35 GP- General Practitioner (Family Medicine physician outside the UK)
- 36 NICE- National Institute of Health and Care Excellence
- 37 OPDW- Outpatient Dataset for Wales (secondary care outpatient appointment dataset)
- 38 PEDW- Patient Episode Dataset for Wales (hospital admission dataset)
- 39 QOF- Quality and Outcomes Framework
- 40 SAIL Secure Anonymised Information Linkage
- 41 SMI- Serious Mental Illness
- 42 WLGP- Welsh Longitudinal General Practice (dataset)

Abstract

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

Background: The use of antipsychotics in primary care is increasing, and more are being used for non-psychotic illnesses. Long-term use of antipsychotics confers increased risk of cardiometabolic disease, so ongoing need should be reviewed regularly by psychiatrists. This study explored changes over time in antipsychotic management and prescribing in primary care, and proportions of patients (≥18 years) prescribed antipsychotics receiving psychiatrist review. **Methods and Findings:** This was a retrospective, population-based observational study using data from the Secure Anonymised Information Linkage databank of approximately 3 million people in Wales (2011 to 2020). Outcomes were prevalence of patients who had received ≥6 antipsychotic prescriptions per year, proportion of patients prescribed antipsychotics who had received psychiatrist review in the preceding 12 months, and proportion of patients prescribed antipsychotics who were registered on the UK Primary Care Serious Mental Illness, Depression and/or Dementia registers, or were not on these registers. The prevalence of adults prescribed antipsychotics increased from 1.06% (95%CI 1.04 to 1.07%) in 2011 to 1.45% (95%Cl 1.43 to 1.46%) in 2020; 1 in 69 adults were prescribed antipsychotics in 2020. The proportion of adults taking antipsychotics solely managed by primary care increased from 40% (95%CI 39 to 41%) in 2011 to 48% (95%CI 47 to 49%) by 2020. The proportion of antipsychotics prescribed to patients not on the Serious Mental Illness register increased from 50% (95%CI 49 to 51%) in 2011 to 56% (95%CI 56 to 57%) by 2020, meaning many patients may not be monitored for the cardiometabolic risk from antipsychotics.

- 66 **Conclusions**: Antipsychotic prescribing is increasing. More people are solely managed by
- 67 general practitioners without psychiatrist review and are not on relevant disease registers,
- so are less are likely to undergo vital cardiometabolic monitoring. These trends pose risks for
- 69 patients and need to be addressed urgently.

Introduction

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

88

89

90

91

92

Antipsychotic medication (APM) is licenced in the United Kingdom (UK) for the management of serious mental illness (SMI) such as schizophrenia and bipolar disorder [1]. Some atypical APMs have extended U.K. licences for treatment of depression (quetiapine) and short-term behavioural management in dementia (risperidone) [2]. APMs are increasingly prescribed off-licence by psychiatrists, often long-term for the management of other conditions, including personality disorder [3], behavioural management in learning disability [4], autism[5] and anxiety [6], despite this contravening best practice guidelines issued by the U.K. National Institute of Health and Care Excellence (NICE) [3, 7, 8]. APMs are effective medications for SMI, but increase risk of obesity [9], type-2 diabetes mellitus [10] and cardiovascular disease [11] when used long-term [12]. Specialist psychiatric review of APM should be undertaken regularly to prevent inappropriate overuse, given patients with SMI die 15-20 years earlier, mainly due to increased rates of cardiovascular disease [13-15], of which APM use is an independent risk factor [16, 17]. General practitioners (GPs) in the U.K. mainly provide physical health reviews of patients with psychotic illness taking APMs [13, 18]. These are conducted via annual recall of patients with diagnostic codes that include them on the U.K. Quality Outcomes Framework (QOF) primary care serious mental illness (QOF SMI) register (which is termed a 'mental health' register but focusses entirely on patients with psychotic illnesses and those prescribed lithium). QOF is a national performance management and funding mechanism to establish disease registers of patients who require additional monitoring and support due to existing chronic disease, and forms part of the GP primary care contract in the UK (now excluding Scotland) [19] (see Table S1). The QOF SMI annual review includes monitoring of alcohol

consumption, smoking, body mass index, blood pressure, blood glucose and lipids, to detect patients with SMI at risk of developing cardiometabolic diseases [13]. However, patients taking APM for dementia, depression and conditions such as anxiety or personality disorder are not captured on the QOF SMI register, and so risk being missed for cardiometabolic monitoring: a cohort study of 47,724 patients in 2016 reported that <50% patients taking APM are using these for a psychotic diagnosis and thus may miss monitoring [7]. GPs report they lack the skills needed to manage APM independently (e.g., alter dose, switch, or stop APM) that is normally provided by psychiatrists who have the expertise to undertake this review [18, 20, 21]. Patients who are initiated on APM by psychiatrists are often then discharged and followed up by primary care; a cohort study estimated that 31% of patients with SMI were managed solely by primary care in 2009 [22]. These patients may take APM long-term with no opportunity for regular psychiatric review. This study aims to answer the following questions:

- 1. Has the prevalence of long-term APM use in primary care changed over the decade just before the COVID-19 pandemic?
- 2. Has the proportion of patients prescribed long-term APM receiving specialist psychiatric review changed over this period?
- 3. Are there differences in the proportion of people prescribed APMs that are included on QOF SMI, depression, and dementia registers in 2020 compared to 2011?

Methods 114 Study design 115 This is a longitudinal, retrospective observational study, undertaken with reference to the 116 117 'Strengthening the Reporting of Observational Studies in Epidemiology' (STROBE) guidelines [23]. 118 119 120 Study population and setting Individuals registered with a GP practice providing data to the Secure Anonymised 121 122 Information Linkage (SAIL) databank formed the population. Analysis focused on adult use (≥18 years), broken down by main psychiatric speciality: general adult psychiatry (patients 123 124 aged 18-64 years) and older adult psychiatry (patients aged ≥65 years). The prevalence of 125 long-term APM use was defined by identifying patients who had APM prescriptions issued on ≥6 separate days in each calendar year. For each individual, their status on the annual 126 date of 1st January was used to determine age (calculated using their week of birth). 127 128 We defined psychiatrist review as occurring where there is a record of a psychiatrist clinic 129 contact with a registered medical practitioner or advanced nurse practitioner (including 130 general adult-, older adult-, child and adolescent-, forensic- or learning disability psychiatry, 131 and psychotherapy subspecialties), or psychiatric hospital admission in the 12 months preceding the year of long-term APM use. If neither outpatient contact nor hospital 132 admission occurred, then we defined APM management as being solely provided by GPs. So, 133 for example, an individual who on 1st January 2019 had ≥6 calendar events of APM issue, 134 was counted as a denominator case, and if in the 12 months preceding this date, they had 135

either psychiatric hospital admission or outpatient contact, they would be counted as a numerator case. Two health boards of the seven in Wales did not provide complete psychiatric outpatient clinic returns for the entire study period; therefore, analysis of the proportions of patients prescribed APM who had received psychiatrist review was limited to the five health boards providing complete returns for 2011-2020. The COVID-19 pandemic resulted in the suspension of many hospital outpatient clinic services, hence we focused on APM management between 1/1/2011 and 1/1/2020.

Data sources

The SAIL databank was used in this study. This is an expanding data repository of 500 million anonymised and encrypted individual-level records from primary and secondary health care sources, and sociodemographic data relevant to health and well-being. This includes national datasets covering the whole of Wales (approximately 3 million population) [24-28]. Patients registered with GP practices providing data to SAIL were examined using the Welsh Longitudinal General Practice (WLGP) dataset. Currently (2024), 86% of Welsh general practices provide data to SAIL, covering 83% of the Welsh population. Attendance at outpatient psychiatric clinic was determined from the Outpatient Dataset for Wales (OPDW). Admission to psychiatric hospital was ascertained using the Patient Episode Dataset for Wales (PEDW). SAIL databank has been validated for use in studies on SMI in earlier studies [15].

Relevant diagnoses for inclusion in QOF SMI, depression and dementia registers recorded in GP records and prescriptions for APMs (with a licence for use in the UK in the study period as listed in the British National Formulary [2]) were extracted using 5-digit Read Codes (v2) in WLGP (see repository for all relevant coding algorithms:

https://github.com/alanwoodall/AMP-Epidemiology). Discussion with two independent consultant psychiatrists from general adult and old-age psychiatry subspecialities confirmed that two APMs were rarely prescribed for psychiatric purposes in the UK and are almost exclusively used for non-psychiatric purposes: prochlorperazine (antiemetic) and levomepromazine (palliative care); these were excluded from analysis of total APM use.

Analysis

The primary outcome measure was the number of adults issued a prescription for an APM on ≥6 separate days in each calendar year. Further analysis was undertaken to determine variation in annual prevalence of APM prescribing, QOF disease register coding and main locus of care by psychiatric speciality cohort as age (categorised into those aged 18-64 years, and those aged ≥65 years) for most analyses, to mirror the conventional UK division of care between general adult- and old-age psychiatric subspecialties. The prevalence of the six most common APMs prescribed from primary care over the study period were determined. With regard to the number of people on APM receiving psychiatrist review, we undertook sensitivity analysis varying the period to capture psychiatric review occurrence. The number of patients who had a lifetime history of relevant psychiatric diagnostic codes that would cause inclusion on the QOF SMI, QOF dementia and/or QOF depression registers was determined, along with the number of patients on each disease register prescribed long-

181

182

183

184

185

186

187

188

189

190

191

192

193

194

195

196

term APM. These three psychiatric illness QOF registers cover diagnoses for the majority of potential licensed uses of APM in the United Kingdom [2]. The number of patients prescribed APM not on any of these three psychiatric QOF-registers was also determined. For each year, we determined the proportion of total APM use for patients included in these four register subsets. Statistical analysis Statistical analysis was undertaken using StatsDirect (Version 4.0.1, www.statsdirect.com). The Clopper-Pearson method was used for confidence intervals of binomial proportions [29]. Differences between binomial proportions were evaluated using the Miettinen-Nurminen method [30]. Results are presented as the main effect with a 95% confidence interval. A 5% significance level was used to test specific, pre-defined comparisons. Patient and public involvement Oversight of the study, data analysis and reporting were made with patient and public advisors who serve on advisory panels for research with the Mental Health Research for Innovation Centre (M-RIC). One author (PS) is a public advisor.

Results

197

198

199

200

201

202

203

204

205

206

207

208

209

210

211

212

213

Changes in Prevalence of APM prescribing between 2011 and 2020 Table 1 shows the prevalence of long-term APM exposure in the population in 2011 and 2020 (annual trends are shown in Figure S1). The number of adults ≥18 years exposed to APM increased from 1.06% to 1.45%. This increase is more marked in the 18-64 years population (0.92% in 2011 increasing to 1.46% in 2020). Of individual APMs, quetiapine was the most prescribed APM in this population (increasing from 0.27% in 2011 to 0.64% in 2020), accounting for 75% of the relative increase in APM exposure. For the ≥65 years population, the prevalence of APM exposure has fallen from 1.51% in 2011 to 1.42% in 2020. Risperidone is now the most prescribed APM in the ≥ 65 years population (increasing from 0.17% in 2011 to 0.36% in 2020). Table S2 shows the counts of patients (all ages) receiving long-term APM listed in the British National Formulary in 2011 and 2020, and their licensed indications. The proportion of total long-term APM exposure that is accounted for by 'second generation' or 'atypical' APMs increased from 79.7% in 2011 to 91.7% in 2020. Approximately 94% of total APM exposures in 2020 are accounted for by 6 individual APMs: quetiapine (37.3%), olanzapine (22.6%), risperidone (15.3%) aripiprazole (12.9%), amisulpride (3.6%) and haloperidol (2.5%).

		All antip	sychotics	Queti	apine	Olanz	apine	Risper	ridone	Amisu	lpride	Aripip	razole	Halop	eridol
	Year	2011	2020	2011	2020	2011	2020	2011	2020	2011	2020	2011	2020	2011	2020
	Counts, (r/n)	21,907/	31,946/	6,349/	12.328/	5,412/	7,520/	3,236/	5,020/	1,531/	1,190/	1,354/	4,263/	991/	825/
		2,076,839	2,206,635	2,076,839	2,206,635	2,076,839	2,206,635	2,076,839	2,206,635	2,076,839	2,206,635	2,076,839	2,206,635	2,076,839	2,206,635
All adults	Prevalence,	1.055	1.448	0.306	0.559	0.261	0.341	0.156	0.227	0.074	0.054	0.065	0.193	0.044	0.038
(≥ 18 years)	% (95% CI)	(1.041,	(1.432,	(0.298,	(0.549,	(0.254,	(0.333,	(0.150,	(0.221,	(0.070,	(0.051,	(0.062,	(0.187,	(0.041,	(0.035,
(2 10 years)		1.069)	1.464)	0.313)	0.569)	0.268)	0.348)	0.161)	0.234)	0.078)	0.057)	0.069)	0.199)	0.047)	0.040)
	Difference,	+0.393		+0.	253	+0.	080	+0.	071	-0.0	020	+0.	128	-0.0	007
	%, (95% CI)	(+0.372	, +0.414)	(+0.241	, +0.266)	(+0.070, +0.091)		(+0.063,	(+0.063, +0.080)		(-0.025, -0.015)		, +0.135)	(-0.014, -0.006,)	
	Counts, (r/n)	14,781/	23,838/	4,290/	10,453/	4,237/	5,509/	2,457/	2,938/	800/	809/	1,097/	3,398/	535/	534/
		1,605,559	1,634.511	1,605,559	1,634.511	1,605,559	1,634.511	1,605,559	1,634.511	1,605,559	1,634.511	1,605,559	1,634.511	1,605,559	1,634.511
General	Prevalence,	0.921	1.458	0.267	0.640	0.264	0.337	0.153	0.180	0.050	0.050	0.068	0.204	0.033	0.033
Adults	% (95% CI)	(0.906,	(1.444,	(0.259,	(0.627,	(0.256,	(0.328,	(0.147,	(0.173,	(0.047,	(0.046,	(0.064,	(0.197,	(0.031,	(0.030,
(18-64 years)		0.936)	1.477)	0.275)	0.652)	0.272)	0.346)	0.159)	0.186)	0.053)	0.053)	0.072)	0.211)	0.036)	0.036)
	Difference,	+0.	.537	+0.373		+0.073		+0.027		0.000		+0.136		0.000	
	%, (95% CI)	(+0.514	, +0.561)	(+0.358,	+0.387)	(+0.061,	+0.085)	(+0.018, +0.036)		(-0.005, +0.005)		(+0.131,	+0.148)	(-0.000,	+0.000)
	Counts, (r/n)	7,126/	8,108/	1,914/	1,876/	1,175/	2,011/	779/	2,082/	730/	381/	267/	875/	456/	291/
		471,280	572,124	471,280	572,124	471,280	572,124	471,280	572,124	471,280	572,124	471,280	572,124	471,280	572,124
011 411	Prevalence,	1.512	1.417	0.406	0.328	0.249	0.352	0.165	0.364	0.155	0.067	0.057	0.153	0.097	0.051
Older Adults	% (95% CI)	(1.477,	(1.387,	(0.388,	(0.313,	(0.236,	(0.337,	(0.154,	(0.348,	(0.144,	(0.060,	(0.050,	(0.143,	(70.088,	(0.045,
(≥ 65 years)		1.547)	1.448)	0.424)	0.343)	0.264)	0.367)	0.177)	0.380)	0.167)	0.073)	0.064)	0.163)	0.011)	0.057)
	Difference,	-0.	095	-0.0	078	+0.	103	+0.199		-0.088		+0.096		-0.046	
	%, (95% CI)	(-0.141	, -0.049)	(-0.101,	-0.055)	(+0.081,	+0.124)	(+0.178	, 0.219)	(-0.101, -0.076)		(+0.835, +0.109)		(-0.056, -0.037)	

Table 1: APM prevalence changes between 2011 and 2020. Analysis based on number of patients prescribed regular APM, (r), as a proportion of the at-risk population in a calendar year, (n).

Proportion of patients prescribed APM receiving psychiatric specialist review.

The percentage of adult patients taking APM who received specialist psychiatric review in the 12 months preceding each year (2011-2020) fell from 59.6% to 52.0%; nearly half of all adults prescribed APM were not receiving annual psychiatrist review (Table 2; annual trends are shown in Figure S2). When analysed by psychiatric subspecialty, the proportion of 18−64 year old patients taking regular APM between 2011-2020 that received psychiatrist review in the previous year fell from 65.7% to 55.0%. The greatest decrease in psychiatrist review occurred in patients prescribed quetiapine (-17.0%). For the ≥65 years population, less than half of patients underwent specialist psychiatric review, decreasing from 47.5% in 2011 to 43.4% in 2020. The greatest decrease was seen for those taking amisulpride (-18.2%).

		All antip	sychotics	Queti	apine	Olanz	apine	Risper	ridone	Amisu	lpride	Aripip	razole	Halop	eridol
	Year	2011	2020	2011	2020	2011	2020	2011	2020	2011	2020	2011	2020	2011	2020
	Patients reviewed	9,574/	11,894/	2,978/	4,539/	2,362/	2,736/	1,428/	1,750/	751/	504/	787/	2,102/	390/	311/
	by psychiatrist,	16,053	22,855	4,786	8,940	3,698	5,272	2,466	3,607	1,146	919	974	3,191	813	593
Adults	r/n														
Aduits (≥18	Patients reviewed	59.6	52.0	62.2	50.8	63.9	51.9	57.9	48.5	65.5	54.8	80.8	65.9	48.0	52.5
years)	by psychiatrist, %,	(58.9-60.4)	(51.4-52.7)	(60.8-63.6)	(49.7-51.8)	(62.3-65.4)	(50.6-53.2)	(56.0-59.8)	(46.9-50.2)	(62.7-68.2)	(51.6-58.0)	(78.2-83.2)	(64.2-67.5)	(44.6-51.4)	(48.4-56.5)
years)	(95% CI)														
	Difference, %,	-7.6 (-8	3.6, -6.6)	-11.4 (-1	3.2, -9.7)	-12.0 (-1	4.0, -9.9)	-9.4 (-12	2.0, -6.8)	-10.7 (-1	4.9, -6.5)	-14.9(-17	'.8, -11.9)	+4.5 (-0	.8, +9.8)
	(95% CI)														
	Patients reviewed	7,028/	9,358/	2,315/	3,945/	1,901/	2,104/	1,124/	1,110/	432/	384/	679/	1,775/	263/	223/
	by psychiatrist,	10,691	17,013	3,339	7,538	2,900	3,882	1,903	2,141	585	609	818	2,593	431	357
General	r/n														
Adults	Patients reviewed	65.7	55.0	69.3	52.3	65.6	54.2	59.1	51.8	73.8	63.1	83.0	68.5	61.0	62.5
(18-64	by psychiatrist, %,	(64.8-66.6)	(54.3-55.8)	(67.8-70.9)	(51.2-53.5)	(63.8-67.3)	(52.6-55.8)	(56.9-61.3)	(49.7-54.0)	(70.3-77.4)	(59.2-66.9)	(80.4-85.6)	(66.7-70.2)	(56.4-65.6)	(57.4-67.5)
years)	(95% CI)														
	Difference, %,	-10.7 (-1	.1.7, -9.5)	-17.0 (-19.0, -15.0)		-11.4 (-13.7, -9.0)		-7.3 (-10.3, -4.2)		-10.7 (-16.1, -5.5)		-14.5 (-18.1, -11.0)		+1.5 (-8.3, +5.4)	
	(95% CI)														
	Patients reviewed	2,546/	2,536/	663/	594/	461/	632/	304/	640/	319/	120/	108/	327/	127/	88/
	by psychiatrist,	5,362	5842	1,447	1,402	798	1,370	563	1,466	561	310	156	598	382	236
	r/n														
Older	Patients reviewed	47.5	43.4	45.8	42.4	57.8	46.1	54.0	43.7	56.9	38.7	69.2	54.7	33.2	37.3
Adults	by psychiatrist, %,	(46.1-48.8)	(42.1-44.7)	(43.3-48.4)	(39.8-45.0)	(54.3-61.2)	(43.5-48.8)	(49.9-58.1)	(41.1-46.2)	(52.8-61.0)	(33.3-44.1)	(62.0-76.5)	(50.7-58.7)	(28.5-38.0)	(31.1-43.5)
(≥65	(95% CI)														
years)	Difference, %, (95% CI)	-4.1 (-5	5.9, -2.2)	-3.4 (-7.	.1, +2.0)	-11.7 (-16.0, -7.3)		-10.3 (-15.2, -5.5)		-18.2 (-25.1, -11.2)		-14.5 (-23.3, -5.8)		+4.1 (-11.8, +3.7)	

Table 2: Proportion of patients taking regular APM who have had a specialist psychiatrist review in previous 12 months. Analysis based on number of patients prescribed APM who had received psychiatrist review, (r), as a proportion of the number of patients prescribed APM in that calendar year, (n).

237

238

239

240

241

242

243

244

245

246

247

248

249

250

251

252

253

254

We conducted a sensitivity analysis of psychiatric follow up by varying the period of time allowed between 1 week and up to 5 years prior to 1/1/2020 to confirm data patterns (Figure S3). Of those aged 18-64 years prescribed long-term APM in 2020, 22.9% had no psychiatrist review in the previous 5 years There was variability based on individual APM; those most likely to have had psychiatric review were prescribed aripiprazole (88.5%), while those least likely were prescribed risperidone (70.9%). For those aged >65 years, 29.9% of those taking APM long-term in 2020 had no evidence of psychiatrist review in the previous 5 years. Again, there was variability based on individual APM: those most likely to have had a review were prescribed aripiprazole (84.4%), while those least likely were prescribed haloperidol (61.9%). Proportions of patients on the psychiatric QOF registers prescribed long-term APM. In 2020, nearly 1 in 63 (1.59%) adults ≥18 years had a lifetime diagnostic code that triggered inclusion on the QOF SMI register, (+0.17% since 2011); 1 in 5 adults (20.7%) had a lifetime diagnostic code that trigged inclusion on the QOF depression register (+5.6% since 2011); 1 in 130 adults (0.77%) had a lifetime diagnostic code that triggered inclusion on the QOF dementia register (+ 0.1% since 2011) (Table 3). For adults not on these three psychiatric illness QOF registers, the proportion fell from 83.7% in 2011, to 78.1% in 2020.

QOF Registers	Year	2011	2020		
	Counts (r/n)	29,487 /	35,105 /		
		2,076,839	2,206,635		
Serious Mental Illness	Prevalence (95% CI) %	1.42 (1.40, 1.44)	1.59 (1.57, 1.61)		
	Difference (95%CI)%	+0.17 (+0.	15, +0.19)		
	Counts (r/n)	313,156 /	457,709 /		
		2,076,839	2,206,635		
Depression	Prevalence (95% CI)%	15.1 (15.0, 15.1)	20.7 (20.7, 20.8)		
	Difference (95%CI) %	+5.6 (+5	.6, +5.7)		
	Counts (r/n)	14,028 /	16,902 /		
		2,076,839	2,206,635		
Dementia	Prevalence (95% CI) %	0.68 (0.66, 0.69)	0.77 (0.76, 0.78)		
	Difference (95%CI) %	+0.09 (+0.	07, +0.11)		
	Counts (r/n)	1,739,328 /	1,722,532 /		
		2,076,839	2,206,635		
None of the above	Prevalence (95% CI) %	83.8 (83.7, 83.8)	78.1 (78.0, 78.1)		
	Difference (95%CI) %	-5.7 (-5	8, -5.6)		

Table 3: Quality and Outcomes Framework registration prevalence changes for persons aged ≥18 years between 2011 and 2020. Analysis is based on the number of patients (r) who have ever been the relevant register, as a proportion of the at-risk population (n) in the calendar year.

Table 4 shows the proportion of adults (≥18 years) prescribed long-term APM listed in the different QOF register categories (annual trends are shown in Figure S4). For patients on the QOF SMI register, the proportion prescribed APM increased to 39.6% in 2020 (+2.6% since 2011), with olanzapine being the most common exposure in 2020 (11.9%; +0.08% since 2011). For those on the QOF dementia register, the proportion prescribed APM decreased significantly from 16.7% in 2011 to 12.9% in 2020. Risperidone was the most common APM exposure in this group in 2020 (5.45%; +3.85% since 2011). For those on the QOF depression register, the proportion prescribed APM increased from 3.37% in 2011 to 4.12% by 2020; the most common APM exposure in this group in 2020 was to quetiapine (1.91%; +0.78% since

- 271 2011). For patients not on any of these three QOF psychiatric illness registers, the proportion
- prescribed APM increased from 0.26% in 2011 to 0.36% in 2020; the most common APM
- exposure in this group in 2020 was to quetiapine (0.13%, +0.06% since 2011).

	Dogistore		All antip	sychotics	Quetia	apine	Olanz	apine	Rispe	idone	Amisu	Ipride	Aripip	razole	Halop	eridol	
	Registers	Year	2011	2020	2011	2020	2011	2020	2011	2020	2011	2020	2011	2020	2011	2020	
		County (m/m)	10,960/	13,915/	2,614/	4,024/	3,498/	4,180/	1,680/	1,771/	846/	846/	974/	2,549/	423/	448/	
		Counts (r/n)	29,487	35,105	29,487	35,105	29,487	35,105	29,487	35,105	29,487	35,105	29,487	35,105	29,487	35,105	
	Serious Mental	Duomoution	37.17	39.74	8.87	11.49	11.86	11.94	5.70	5.06	2.87	2.42	3.30	7.28	1.44	1.28	
	Illness	Proportion (95% CI)%	(36.62,	(39.23,	(8.54,	(11.16,	(11.49,	(11.60,	(5.43,	(4.83,	(2.68,	(2.26,	(3.10,	(7.01,	(1.30,	(1.16,	
	illiess	(95% CI)%	37.72)	40.25)	9.19)	11.83)	12.23)	12.28)	5.96)	5.29)	3.06)	2.58)	3.51)	7.55)	1.57)	1.40)	
		Difference (95%CI)%	+2.57 (+1.72, +3.22)		+2.62 (+2.2	13, +3.07)	+0.08 (-0.	46, +0.55)	-0.64 (-1.	17, -0.48)	-0.45 (-0.	71, -0.21)	+3.98 (+3.	61, +4.31)	-0.16 (-0.3	34, +0.02)	
			10,552/	18,852/	3,546/	8,754/	2,773/	4,371/	1,336/	2,028/	619/	559/	738/	2,529/	307/	329/	
		Counts (r/n)	313,156	457,709	313,156	457,709	313,156	457,709	313,156	457,709	313,156	457,709	313,156	457,709	313,156	457,709	
	Depression	D	3.37	4.12	1.13	1.91	0.89	0.96	0.43	0.44	0.20	0.12	0.24	0.55	0.10	0.07	
roportion		Proportion (95% CI)%	(3.31,	(4.06,	(1.10,	(1.87,	(0.85,	(0.93,	(0.41,	(0.42,	(0.18,	(0.11,	(0.22,	(0.53,	(0.09,	(0.06,	
f patients		(95% CI)%	3.43)	4.18)	1.17)	1.95)	0.92)	0.98)	0.45)	0.46)	0.21)	0.13)	0.25)	0.57)	0.11)	0.08)	
on QOF registers		Difference (95%CI)%	+0.75 (+0.	66, +0.83)	+0.78 (+0.7	72, +0.84)	+0.07 (+0.	03, +0.11)	+0.01 (-0.	01, +0.05)	-0.08 (-0.	09, -0.06)	+0.31 (+0.	29, + 0.35)	-0.03 (-0.	.04, -0.01)	
rescribed		Counts (n/n)	2,344/	2,174/	951/	430/	165/	326/	210/	904/	304/	100/	70/	209/	161/	72/	
APM		Counts (r/n)	14,028	16,902	14,028	16,902	14,028	16,902	14,028	16,902	14,028	16,902	14,028	16,902	14,028	16,902	
		Proportion	16.71	12.86	6.78	2.54	1.18	1.93	1.50	5.35	2.17	0.59	0.50	1.24	1.15	0.43	
	Dementia	(95% CI)%	(16.10,	(12.37,	(6.36,	(2.32,	(1.01,	(1.73,	(1.30,	(5.02,	(1.94,	(0.48,	(0.40,	(1.07,	(0.98,	(0.33,	
		(95% CI)%	17.34)	13.38)	7.20)	2.79)	1.37)	2.15)	1.70)	5.70)	2.42)	0.71)	0.63)	1.40)	1.34)	0.52)	
		Difference (95%CI)%	-3.85 (-4.	64, -3.06)	-4.24 (-4.7	70, -3.77)	+0.75 (+0.	+0.75 (+0.47, +1.03)		+3.85 (+3.43, +4.27)		83, -1.32)	+0.74 (+0.53, +0.95)		-0.72 (-0.92, -0.53)		
		Counts (r/n)	4,441/	6,147/	1,206/	2,170/	750/	1,120/	872/	1,585/	245/	149/	144/	611/	315/	205/	
		Counts (1/11)	1,739,328	1,722,532	1,739,328	1,722,532	1,739,328	1,722,532	1,739,328	1,722,532	1,739,328	1,722,532	1,739,328	1,722,532	1,739,328	1,722,532	
	None of the	Proportion	0.255	0.357	0.069	0.126	0.043	0.065	0.050	0.092	0.014	0.009	0.008	0.036	0.018	0.012	
	above	(95% CI)%	(0.248,	(0.348,	(0.065,	(0.012,	(0.040,	(0.061,	(0.047,	(0.088,	(0.012,	(0.007,	(0.007,	(0.033,	(0.016,	(0.010,	
		,	0.263)	0.366)	0.0730	0.013)	0.046)	0.069)	0.054)	0.097)	0.016)	0.010)	0.010)	0.038)	0.0200	0.014)	
		Difference (95%CI)%	+0.102 (+0.0	090, +0.011)	+0.057 (+0.0	+0.057 (+0.051, +0.063)		+0.022 (+0.017, +0.027)		+0.042 (+0.036, +0.048)		-0.005 (-0.008, -0.003)		+0.028 (+0.024, 0.030)		-0.006 (-0.009, -0.004)	

Table 4: Changes in APM use in adult patients (≥18 years) with a lifetime code on the QOF Serious Mental Illness, depression and/or dementia registers, and those who are not on any of these three psychiatric illness QOF registers, between 2011 and 2020. The number of patients with a lifetime code on the relevant QOF registers exposed to APM, (r), is expressed as a proportion of the total population with a lifetime code for inclusion on each QOF register, (n).

281

282

283

284

285

286

287

288

289

290

291

292

293

294

295

Proportion of overall long-term APM use by QOF register status Table 5 shows the proportion of overall long-term APM use for patients who are registered on the QOF SMI, QOF dementia, and/or QOF depression registers, and the proportion of overall long-term APM use for patients not on any of these three QOF psychiatric illness registers (annual trends are shown in Figure S5). The proportion of overall APM use prescribed for patients on the QOF SMI register fell from 50.0% in 2011 to 43.6% by 2020; the lowest proportion was quetiapine (32% in 2020). The proportion of overall APM use for patients on the QOF dementia register fell from 10.7% in 2011 to 6.8% in 2020;, nearly 18% of all long-term risperidone use is for patients on the QOF dementia register. The proportion of APM use prescribed to patients who are registered on the QOF depression register increased from 48.2% in 2011 to 59.0% by 2020; For quetiapine, 71% of total use in 2020 was for patients who have been on the QOF depression register during their life, a 15% increase from 2011 to 2020. The proportion of APM prescribed for patients not on these three registers fell slightly (20.2% in 2011 to 19.2% in 2020). The proportion of haloperidol use was greatest for this group (34.6% in 2011, decreasing to 24.9% in 2020).

	OOF Pagistans		All antip	sychotics	Quetia	oine	Olan	zapine	Rispe	idone	Amisu	lpride	Aripip	razole	Halop	peridol
	QOF Registers	Year	2011	2020	2011	2020	2011	2020	2011	2020	2011	2020	2011	2020	2011	2020
		Counts (r/n)	10,960/ 21,907	13,915/ 31946	2,614/ 6,349	4,024/ 12,328	3,498/ 5,412	4,180/ 7,520	1,680/ 3,236	1,771/ 5,020	846/ 1,530	846/ 1,190	974/ 1,354	2,549/ 4,263	423/ 911	448/ 825
	Serious Mental Illness	Prevalence (95% CI) %	50.03 (49.37, 50.69)	43.56 (43.01, 44.10)	41.17 (39.97, 42.39)	32.64 (31.82, 33.47)	64.63 (63.35, 65.90	55.59 (54.46, 56.71)	51.92 (50.19, 53.63)	35.28 (33.97, 36.61)	55.29 (52.79, 57.77)	71.09 (68.45, 73.67)	71.94 (69.48, 74.33)	59.79 (58.31, 61.27)	46.43 (43.22, 49.68)	54.3 (50.8 57.6
		Difference (95%CI) %	-6.47 (-7.33, -5.61)		-8.53 (-9.98	,		1.77, -7.33)	-16.64 (-18	•	+15.80 (+12	,	,	5.10, -9.18)	+7.87 (+3.	
	Depression	Counts (r/n)	10,552/ 21,907	18,852/ 31,946	3,546/ 6,349	8,754/ 12,328	2,773/ 5,412	4,371/ 7,520	1,336/ 3,236	2,028/ 5,020	619/ 1,530	559/ 1,190	738/ 1,354	2,529/ 4,263	307/ 911	329 825
Proportion of total APM		Prevalence (95% CI) %	48.17 (47.51, 48.83)	59.01 (58.47, 59.55)	55.85 (54.63, 57.07)	71.01 (70.21, 71.80)	51.24 (49.91, 52.57)	58.18 (57.01, 59.24)	41.29 (39.59, 42.98)	40.40 (39.05, 41.76)	40.46 (38.00, 42.92)	46.97 (44.15, 49.82	54.51 (51.84, 57.16)	59.32 (57.85, 60.80)	33.70 (30.70, 36.83)	39.9 (36.5 43.20
		Difference (95%CI) %	+10.84 (+9.99, +11.70) +15.16			+15.16 (+13.72, +16.59)		.15, +8.63)	-0.89 (-3.	06, +1.28)	+6.51 (+2.7	76, +10.27)	+4.81 (+1	80, +7.84)	+6.28 (+1.	64, +10.7
prescribing by register	Dementia	Counts (r/n)	2,344/ 21,907	2,174/ 31,946	951/ 6,349	430/ 12,328	165/ 5,412	326/ 7,520	210/ 3,236	904/ 5,020	304/ 1,530	100/ 1,190	70/ 1,354	209/ 4,263	161/ 911	72/ 825
		Prevalence (95% CI) %	10.70 (10.29, 11.11)	6.81 (6.53, 7.09)	14.98 (14.11, 15.88)	3.49 (3.18, 3.83)	3.05 (2.62, 3.54)	4.34 (3.90, 4.82)	6.49 (5.69, 7.39)	18.01 (16.97, 19.07)	19.87 (17.95, 21.94)	8.40 (6.96, 10.13)	5.17 (4.11, 6.48)	4.90 (4.29, 5.59)	17.67 (15.33, 20.28)	8.73 (7.00 10.8
		Difference (95%CI) %	-3.89 (-4.	37, -3.42)	-11.49 (-12.2	8, -10.70)	+1.29 (+0	.60, +1.94)	+11.52 (+10.01, +13.03)		-11.47 (-14.16, -8.77)		-0.27 (-1.60, +1.06)		-8.94 (-12.16, -5.73	
		Counts (r/n)	4,441/ 21,907	6,147/ 31,946	1,206/ 6,349	2,170/ 12,328	750/ 5,412	1,120/ 7,520	872/ 3,236	1,585/ 5,020	245/ 1,530	149/ 1,190	144/ 1,354	611/ 4,263	315/ 911	205, 825
	None of the above	Prevalence (95% CI) %	20.27 (19.74, 20.81)	19.24 (18.81, 19.67)	19.00 (18.05, 19.98)	17.60 (16.94, 18.28)	13.86 (12.96, 14.80)	14.89 (14.11, 15.72)	26.95 (25.42, 28.48)	31.57 (30.29, 32.86)	16.01 (14.26, 17.94)	12.52 (10.76, 14.52)	10.64 (9.10, 12.39)	14.33 (13.31, 15.42)	34.58 (31.56, 37.72)	24.8 (22.0 27.91
		Difference (95%CI) %	-1.03 (-1.	,	-1.70 (-2.56	· · ·	+1.03 (-0.19, +2.27)		+4.62 (+2.61, +6.65)		-3.49 (-6.16, -0.83)		+3.69 (+1.61, +5.78)		-9.73 (-14.05, -5.41)	

Table 5: Changes in proportion of overall APM use in adult patients (≥18 years) with a lifetime code on the QOF Serious Mental Illness, depression and/or dementia registers, and those who are not on any of these three psychiatric illness QOF registers, between 2011 and 2020. The number of patients with a lifetime code on the relevant QOF registers exposed to APM, (r), is expressed as a proportion of the total number of patients exposed to APM (n).

Discussion 302 303 Principal findings 304 Our study has shown that: 305 (1) The prevalence of long-term APM use increased substantially in the adult population 306 (approximately 1 in 69 adults aged ≥18 years were prescribed long-term APM by 2020), with rises most marked in the 18-64 years group (relative increase between 2011 and 307 2020 was 58%). There is a slight fall in the prevalence of APM use in the ≥65 years 308 309 population (relative decrease between 2011 and 2020 is 6%). (2) For patients prescribed long-term APM, the proportion who had an annual review by a 310 311 psychiatrist fell (relative decrease between 2011 and 2020 was 13%); nearly half of all 312 adults did not have any annual psychiatric review in 2019-2020. This is more pronounced for the \geq 65 years than the 18-64 years group. 313 (3) The proportion of people prescribed long-term APM, who are not on the QOF SMI 314 register increased from 50% in 2011 to 56% by 2020, so decreasing the likelihood of 315 cardiometabolic monitoring and increasing the risk of experiencing adverse effects from 316 APM in the adult population. 317 318 Our work suggests that APM are increasingly used for unlicensed and/or non-psychotic conditions. The decrease in psychiatric reviews of patients prescribed APM, along with 319 increasing use for conditions that are not captured on the QOF SMI register and thus 320 automatically subject to cardiometabolic monitoring, may combine to increase the risk of 321 people becoming 'trapped' on APM in primary care, thus increasing their risk of 322 323 cardiometabolic morbidity and premature mortality.

Strengths and weaknesses of the study

324

325

326

327

328

329

330

331

332

333

334

335

336

337

338

339

340

341

342

343

344

345

346

To our knowledge, this is the first assessment of APM management trends to report the proportions of patients taking these medications who are managed solely in primary care, and first to compare AMP prescribing patterns between different national QOF psychiatric illness registers, and for licenced vs unlicensed use. This study has particular strengths: (1) we focus only on patients who have had ≥6 prescription events annually, to identify patients prescribed long-term APM who are most at risk of cardiometabolic disease. (2) SAIL is a large databank with rich cross-referencing between primary and secondary care (inpatient and outpatient contact) datasets for each patient, so identifying shared management trends by primary care and psychiatric services. Limitations of this study include: (1) SAIL databank obtains data exclusively from NHS Wales services, so caution should be applied when generalising findings to other populations. (2) SAIL databank cannot provide number of tablets issued per script, so quantification of APM burden is limited. (3) We only capture APM exposure where the patient receives a prescription from NHS primary care and do not capture where prescriptions are issued to patients privately, those registered with Armed Forces or prison primary health care services, and those issued directly by secondary care (which will include most intramuscular depot APM prescriptions); the oral APM clozapine is also classified as high risk and licensed in the UK only for issue by psychiatrists so would not be routinely captured [31]; these represent potential missing data in the population we are not able to measure. (4) We have not identified patients being prescribed ≥2 APMs concurrently. (5) With regards to psychiatrist review, our case definitions will not have identified indirect patient management between GPs and psychiatrists (e.g. communication

without seeing the patient), nor will it have identified patient contact with non-prescribing mental health team members who may provide input into APM review (these are, however not able to make APM prescribing changes). (7) Use of lifetime prevalence of diagnostic codes to determine patient exposure to QOF SMI, QOF Dementia and QOF Depression registers, as other studies have done [7], will not detect changes in psychiatric diagnoses that can happen over time (e.g., a person may initially have a diagnosis of schizoaffective disorder (and so be recorded on the QOF SMI register) that is later revised to personality disorder (a diagnosis not captured on the QOF-SMI register, but the patient will still be counted on the QOF-SMI register due to lifetime coding). However, psychiatric codes are often inaccurate and not maintained regularly [32], or removed from GP records when an updated one is added (e.g. the above patient with personality disorder may still have a code of schizoaffective disorder which is not replaced with the new diagnostic code); up to 32% of psychiatric indications for APM use could not be clearly established in a recent study, which limits accuracy [33].

Comparison with other studies and need for future research

We found a significant increase in adults exposed to long-term APM. The prevalences we report are consistent with other studies; Marston *et al* reported that 0.6-0.7% of the population had exposure to APM in their cohort study which ended in 2011 [7]; Shoham *et al* report an APM prevalence of 1.2% in 2014 in a questionnaire survey of those aged ≥16 years [34]. The greatest increase is for quetiapine, which accounted for 44% of all APM exposures in the 18-64 years group by 2020. Despite this increase in APM use, rates of psychiatric illness prevalence (as reported on the 3 psychiatric illness QOF registers) have not

371

372

373

374

375

376

377

378

379

380

381

382

383

384

385

386

387

388

389

390

391

392

increased proportionally in this population; this suggests increasing APM use is for nonpsychotic disorders, such as anxiety, depression and personality disorder, as has been reported elsewhere [3, 7, 33]. Lack of access to appropriate psychological therapies is reported as driving increasing APM use in non-psychotic disorders [18]. Prevalence of longterm APM exposure in the ≥65 years population has decreased slightly, with significant falls in patients with dementia (-3.85% (95%CI: -4.64, -3.06)); this is promising, given the increased risk of mortality reported when APM are used long term in patients with Alzheimer's disease [35]. However, use of long-term risperidone in dementia patients has increased significantly (+3.85% (95%CI +3.43, +4.27). The UK licence for risperidone is for 'short-term treatment (up to 6 weeks) of persistent aggression in patients with moderate to severe Alzheimer's dementia unresponsive to non-pharmacological interventions and when there is a risk of harm to self or others' [2], and yet nearly 1 in 19 patients with dementia are prescribed risperidone long-term; studies report pressure on clinicians to use APM for patients with dementia in care homes, often as a result of shortages of staff trained in nonpharmacological interventions [18].

We found decreasing proportions of patients prescribed APM have had a psychiatric review in the preceding 12 months. One possible explanation may be more APM being prescribed independently by GPs; this study does not allow determination of which clinician initiated APM, but qualitative studies suggest that GPs are not confident to initiate APM without psychiatrist input [18, 21, 36], so we suspect this is unlikely. However, much of the rise in APM use in the 18-64 year group is due to quetiapine; one possibility is the use of low doses quetiapine for sedation instead of benzodiazepines [37] and/or as an adjunct to difficult-to-

394

395

396

397

398

399

400

401

402

403

404

405

406

407

408

409

410

411

412

413

414

415

treat depression by GPs and psychiatrists. Another possible explanation is that more patients are discharged on APM by psychiatrists to primary care, either when the patients with SMI are "stable" from a psychiatric perspective, or when APM are prescribed to patients who do not have psychotic illness, such as personality disorder, anxiety, or depression. This may be due to psychiatrists feeling they do not need to continue specialist input in the patient's care, but many psychiatrists report pressure from managers to discharge all those patients who do not have SMI from their outpatient clinics [18]. Further research to determine APM initiation rates in primary care and management of APM for non-psychotic illness is required. [18, 21, 36] While the prevalence of APM exposure is rising, the proportion of total APM use for patients with a psychotic illness history (inclusion on QOF SMI register) is decreasing; only 44% of APM use in 2020 was for patients with a history of SMI; this is similar to the proportion used for SMI (36%) reported by Marston et al [7]. This supports our concern that APM is being increasingly used long-term for non-psychotic disorders, often off-licence and in contravention of NICE guidelines (e.g. for personality disorder where APM should only be used short-term) [38]. Only the QOF SMI register funds GPs to undertake cardiometabolic monitoring of patients taking APM; 56% of patients prescribed long-term APM are not on this disease register, and GPs are not funded to undertake cardiometabolic monitoring for these patients. We suspect many GPs still perform unfunded cardiometabolic monitoring when APM are used in non-SMI conditions. However, with most cardiometabolic monitoring devolved to GP practices even when a patient remains under secondary care, there is a risk patients taking APM longterm may not have cardiometabolic monitoring undertaken, as primary care utilise

automated QOF SMI register recalls to facilitate this. A patient coded on the QOF SMI register will get annual recall for cardiometabolic monitoring and GP review, whereas patients taking APM who are coded only on the QOF dementia or QOF depression registers do not get automatic recall, as there is no QOF requirement to undertake cardiometabolic monitoring, so this is less likely to happen. For a patient prescribed long-term APM for personality disorders, anxiety, or autism, and thus who is not captured on any QOF psychiatric illness register, there is no funding or automatic recall for GP review, or for cardiometabolic monitoring. GPs are supposed to conduct annual medication reviews, but research shows that these are of often incomplete, often of variable effectiveness, and limited action occurs particularly when APM is involved and there is no ongoing psychiatric input due to GP reluctant to change these medications [18, 21, 36, 39].

Implications for clinicians and policymakers

This study confirms that there is a rising burden of APM use in primary care in the UK, up to 2020. Fewer patients receive annual psychiatric review, as more are discharged to primary care for sole management. More APM is prescribed for off-licence and/or non-psychotic illness that are not captured on the QOF SMI register, meaning cardiometabolic monitoring and specialist review may not occur. There is an urgent need for appropriate resources to be provided so that patients taking APM long-term have access to an annual review with a psychiatrist able to optimise, switch or withdraw APM, and that primary care funding for cardiometabolic monitoring is based on the use of APM, rather than solely due to inclusion on the QOF-SMI register due to diagnosis. Without changes in the provision of such safeguards, there is a risk that increasing numbers of people will remain 'trapped' on APMs

439 long-term without effective psychiatrist review affording the opportunities to stop these

medications, increasing their risk of developing cardiometabolic disease and contributing to

premature mortality in patients with psychiatric illnesses.

440

441

444

445

446

447

448

449

450

451

452

453

454

455

456

457

458

459

460

461

462

463

464

Contributors: AW, IB, SS, LW and FSM conceived and designed the study. AW, IB, SS, LW and FSM obtained funding. AW, AG, and HC acquired and analysed the data. AW interpreted the data. AW drafted the initial manuscript. PS provided patient and public oversight. AW, FSM, LW, IB, SS, AG and PS critically revised the manuscript for important intellectual content. AW and IB did the statistical analyses. AW, AG, and HC had full access to all the data in the study. AW and IB take responsibility for the integrity of the data and the accuracy of the data analysis. They are the guarantors. The corresponding author attests that all listed authors meet authorship criteria and that no others meeting the criteria have been omitted. Funding: AW is funded by a Heath and Care Wales Research Time Award (RTA-NHS-21-02) Ethical Approval: The use of data from the SAIL databank was approved by the SAIL Information Governance Research Panel. As this study did not use person identifiable data no formal NHS research ethics committee approval was required. No data were reported where an output would have <5 individual counts. Dedication: This work is dedicated to the memory of our friend and research colleague, Huw Collins, who sadly died unexpectedly during this project. Acknowledgements: This study makes use of anonymised data held in the Secure Anonymised Information Linkage (SAIL) Databank. We would like to acknowledge all the data providers who make anonymised data available for research. We want to thank members of SAIL, especially Dr Sarah Rees, who supported the researchers during this project. We are also grateful to consultant psychiatrist colleagues Dr Ben Shooter, and Dr Adnan Sharaf, who provided insight into psychiatric APM use in the UK, clinic appointment structures and recall methods.

References

- Roberts R, Neasham A, Lambrinudi C, Khan A. A quantitative analysis of antipsychotic
 prescribing trends for the treatment of schizophrenia in England and Wales. JRSM Open.
 2018; 9(4):2054270418758570. doi: 10.1177/2054270418758570. PubMed PMID: 29707225.
- Joint Formulary Committee. British National Formulary. Treatment Summaries: Psychoses
 and related disorders (online) [Internet]. BMJ and Pharamceutical Press, c2023 [cited 2024
 Jun 1]. Available from: https://bnf.nice.org.uk/treatment-summaries/psychoses-and-related-disorders/.
- Hardoon S, Hayes J, Viding E, McCrory E, Walters K, Osborn D. Prescribing of antipsychotics among people with recorded personality disorder in primary care: a retrospective nationwide cohort study using The Health Improvement Network primary care database.
 BMJ Open. 2022; 12(3): e053943. Epub 2022/03/11. doi: 10.1136/bmjopen-2021-053943.
 PubMed PMID: 35264346; PubMed Central PMCID: PMCPMC8968526.
- 4. Alexander RT, Shankar R, Cooper SA, Bhaumik S, Hastings R, Kapugama CL, et al. Challenges 479 and pitfalls of antipsychotic prescribing in people with learning disability. Br J Gen Pract. 480 2017; 67(661): 372-3. doi: 10.3399/bjgp17X692081.
- Posey DJ, Stigler KA, Erickson CA, McDougle CJ. Antipsychotics in the treatment of autism. J
 Clin Invest. 2008; 118(1):6-14. Epub 2008/01/04. doi: 10.1172/jci32483. PubMed PMID: 18172517; PubMed Central PMCID: PMCPMC2171144.
- Comer JS, Mojtabai R, Olfson M. National Trends in the Antipsychotic Treatment of
 Psychiatric Outpatients With Anxiety Disorders. Am J Psychiatry. 2011; 168(10): 1057-65. doi:
 10.1176/appi.ajp.2011.11010087. PubMed PMID: 21799067.
- 487 7. Marston L, Nazareth I, Petersen I, Walters K, Osborn DPJ. Prescribing of antipsychotics in UK 488 primary care: a cohort study. BMJ Open. 2014; 4(12):e006135. doi: 10.1136/bmjopen-2014-489 006135.
- 490 8. National Institute for Health and Care Excellence. Psychosis and schizophrenia in adults: 491 prevention and management. Clinical guideline. [Internet]. London: NICE, 2014. [cited 2024 492 Jun 1] Available from: https://www.nice.org.uk/guidance/cg178.
- Osborn DP, Petersen I, Beckley N, Walters K, Nazareth I, Hayes J. Weight change over two
 years in people prescribed olanzapine, quetiapine and risperidone in UK primary care:
 Cohort study in THIN, a UK primary care database. J Psychopharmacol. 2018; 32(10): 1098 103. Epub 2018/06/26. doi: 10.1177/0269881118780011. PubMed PMID: 29938561.
- 497 10. Holt RIG. Association Between Antipsychotic Medication Use and Diabetes. Curr Diab Rep.
 498 2019; 19(10): 96. Epub 2019/09/04. doi: 10.1007/s11892-019-1220-8. PubMed PMID:
 499 31478094; PubMed Central PMCID: PMCPMC6718373.
- Correll CU, Solmi M, Veronese N, Bortolato B, Rosson S, Santonastaso P, et al. Prevalence,
 incidence and mortality from cardiovascular disease in patients with pooled and specific
 severe mental illness: a large-scale meta-analysis of 3,211,768 patients and 113,383,368
 controls. World Psychiatry. 2017; 16(2): 163-80. Epub 2017/05/13. doi: 10.1002/wps.20420.
 PubMed PMID: 28498599; PubMed Central PMCID: PMCPMC5428179.
- Ashworth M, Schofield P, Das-Munshi J. Physical health in severe mental illness. Br J Gen Pract 2017; 67(663): 436-7. doi: 10.3399/bjgp17X692621.
- 507 13. Woodall A. Managing patients on atypical antipsychotics in primary care. Prescriber. 2021; 32(11-12): 18-23. doi: https://doi.org/10.1002/psb.1952.
- Hayes JF, Marston L, Walters K, King MB, Osborn DPJ. Mortality gap for people with bipolar disorder and schizophrenia: UK-based cohort study 2000-2014. Br J Psychiatry 2017; 211(3): 175-81. Epub 2017/07/08. doi: 10.1192/bjp.bp.117.202606. PubMed PMID: 28684403; PubMed Central PMCID: PMCPMC5579328.
- John A, McGregor J, Jones I, Lee SC, Walters JTR, Owen MJ, et al. Premature mortality among people with severe mental illness New evidence from linked primary care data. Schizophr

- Res. 2018; 199: 154-62. Epub 2018/05/08. doi: 10.1016/j.schres.2018.04.009. PubMed PMID: 29728293.
- 517 16. Woodall A, Prosser A, Griffiths M, Shooter B, Garfitt J, Walker L, et al. Cardiovascular risk
 518 estimation in rural psychiatric inpatient populations: Cross-sectional preliminary study.
 519 Psychiatry Res Commun. 2023; 3(1): 100103. doi:
 520 https://doi.org/10.1016/j.psycom.2023.100103.
- 17. Hippisley-Cox J, Coupland C, Brindle P. Development and validation of QRISK3 risk prediction algorithms to estimate future risk of cardiovascular disease: prospective cohort study. BMJ.
 2017; 357: j2099. Epub 2017/05/26. doi: 10.1136/bmj.j2099. PubMed PMID: 28536104;
 PubMed Central PMCID: PMCPMC5441081
- Woodall AA, Abuzour AS, Wilson SA, Mair FS, Buchan I, Sheard SB, et al. Management of antipsychotics in primary care: Insights from healthcare professionals and policy makers in the United Kingdom. PLoS One. 2024; 19(3): e0294974. Epub 2024/03/01. doi: 10.1371/journal.pone.0294974. PubMed PMID: 38427674; PubMed Central PMCID: PMCPMC10906843 203986.
- 19. NHS England. Quality and outcomes framework guidance for 2023/24. 2024 [updated 15th
 S31 April 2024; cited 13th June 2024]. Available from: https://www.england.nhs.uk/long-read/quality-and-outcomes-framework-guidance-for-2023-24/
- Cooper RE, Hanratty É, Morant N, Moncrieff J. Mental health professionals' views and
 experiences of antipsychotic reduction and discontinuation. PLoS One. 2019; 14(6)
 :e0218711. Epub 2019/06/21. doi: 10.1371/journal.pone.0218711. PubMed PMID:
 31220160; PubMed Central PMCID: PMCPMC6586401.
- Nash A, Kingstone T, Farooq S, Tunmore J, Chew-Graham C, A. Switching antipsychotics to support the physical health of people with severe mental illness: a qualitative study of healthcare professionals' perspectives. BMJ Open. 2021;11(2):e042497. doi: 10.1136/bmjopen-2020-042497.
- 22. Reilly S, Planner C, Hann M, Reeves D, Nazareth I, Lester H. The role of primary care in service provision for people with severe mental illness in the United Kingdom. PLoS One. 2012; 7(5): e36468. Epub 2012/05/23. doi: 10.1371/journal.pone.0036468. PubMed PMID: 22615769; PubMed Central PMCID: PMCPMC3352919.
- von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. Strengthening
 the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for
 reporting observational studies. BMJ. 2007; 335(7624): 806-8. Epub 2007/10/20. doi:
 10.1136/bmj.39335.541782.AD. PubMed PMID: 17947786; PubMed Central PMCID:
 PMCPMC2034723.
- Jones KH, Ford DV, Jones C, Dsilva R, Thompson S, Brooks CJ, et al. A case study of the Secure Anonymous Information Linkage (SAIL) Gateway: a privacy-protecting remote access system for health-related research and evaluation. J Biomed Inform. 2014; 50(100): 196-204. Epub 2014/01/21. doi: 10.1016/j.jbi.2014.01.003. PubMed PMID: 24440148; PubMed Central PMCID: PMCPMC4139270.
- Ford DV, Jones KH, Verplancke JP, Lyons RA, John G, Brown G, et al. The SAIL Databank:
 building a national architecture for e-health research and evaluation. BMC Health Serv Res.
 2009; 9: 157. Epub 2009/09/08. doi: 10.1186/1472-6963-9-157. PubMed PMID: 19732426;
 PubMed Central PMCID: PMCPMC2744675.
- Lyons RA, Jones KH, John G, Brooks CJ, Verplancke JP, Ford DV, et al. The SAIL databank:
 linking multiple health and social care datasets. BMC Med Inform Decis Mak. 2009; 9: 3.
 Epub 2009/01/20. doi: 10.1186/1472-6947-9-3. PubMed PMID: 19149883; PubMed Central PMCID: PMCPMC2648953.
- Rodgers SE, Demmler JC, Dsilva R, Lyons RA. Protecting health data privacy while using
 residence-based environment and demographic data. Health Place. 2012; 18(2): 209-17.
 Epub 2011/10/15. doi: 10.1016/j.healthplace.2011.09.006. PubMed PMID: 21996431.

- 28. Rodgers SE, Lyons RA, Dsilva R, Jones KH, Brooks CJ, Ford DV, et al. Residential Anonymous Linking Fields (RALFs): a novel information infrastructure to study the interaction between the environment and individuals' health. J Public Health (Oxf). 2009; 31(4): 582-8. Epub 2009/05/19. doi: 10.1093/pubmed/fdp041. PubMed PMID: 19447812.
- 570 29. Newcombe RG. Two-sided confidence intervals for the single proportion: comparison of seven methods. Stat Med. 1998; 17(8): 857-72. Epub 1998/05/22. doi: 10.1002/(sici)1097-0258(19980430)17:8<857::aid-sim777>3.0.co;2-e. PubMed PMID: 9595616.
- 573 30. Miettinen O, Nurminen M. Comparative analysis of two rates. Stat Med. 1985; 4(2): 213-26. 574 Epub 1985/04/01. doi: 10.1002/sim.4780040211. PubMed PMID: 4023479.
- 575 31. Whiskey E, Barnard A, Oloyede E, Dzahini O, Taylor DM, Shergill SS. An evaluation of the variation and underuse of clozapine in the United Kingdom. Acta Psychiatr Scand. 2021; 143(4): 339-47. doi: https://doi.org/10.1111/acps.13280.
- Mansour H, Mueller C, Davis KAS, Burton A, Shetty H, Hotopf M, et al. Severe mental illness diagnosis in English general hospitals 2006-2017: A registry linkage study. PLoS Med. 2020;
 17(9): e1003306. Epub 2020/09/18. doi: 10.1371/journal.pmed.1003306. PubMed PMID:
 32941435; PubMed Central PMCID: PMCPMC7498001
- 582 33. Radojčić MR, Pierce M, Hope H, Senior M, Taxiarchi VP, Trefan L, et al. Trends in antipsychotic 583 prescribing to children and adolescents in England: cohort study using 2000-19 primary care 584 data. Lancet Psychiatry. 2023; 10(2): 119-28. Epub 2023/01/14. doi: 10.1016/s2215-585 0366(22)00404-7. PubMed PMID: 36638816.
- 586 34. Shoham N, Cooper C, Lewis G, Bebbington P, McManus S. Temporal trends in psychotic symptoms: Repeated cross-sectional surveys of the population in England 2000–14. Schizophr Res. 2021; 228: 97-102. doi: https://doi.org/10.1016/j.schres.2020.11.057.
- 589 35. Mok PLH, Carr MJ, Guthrie B, Morales DR, Sheikh A, Elliott RA, et al. Multiple adverse 590 outcomes associated with antipsychotic use in people with dementia: population based 591 matched cohort study. BMJ. 2024; 385: e076268. doi: 10.1136/bmj-2023-076268.
- 592 36. Grünwald LM, Duddy C, Byng R, Crellin N, Moncrieff J. The role of trust and hope in
 593 antipsychotic medication reviews between GPs and service users a realist review. BMC
 594 Psychiatry. 2021; 21(1): 390. Epub 2021/08/06. doi: 10.1186/s12888-021-03355-3. PubMed
 595 PMID: 34348680; PubMed Central PMCID: PMCPMC8340528.
- Kelly M, Dornan T, Pringsheim T. The lesser of two evils: a qualitative study of quetiapine
 prescribing by family physicians. CMAJ Open. 2018; 6(2): E191-e6. Epub 2018/05/02. doi:
 10.9778/cmajo.20170145. PubMed PMID: 29712643; PubMed Central PMCID:
 PMCPMC7869656.
- National Institute for Health and Care Excellence. Bordeline Personality DIsorder: regonition and treatment. Clinical guideline. [Internet]. London: NICE, 2009. [cited 2024 Jun 1] Available from: https://www.nice.org.uk/guidance/cg78
- 603 39. Abuzour AS, Wilson SA, Woodall AA, Mair FS, Clegg A, Shantsila E, et al. A qualitative 604 exploration of barriers to efficient and effective Structured Medication Reviews in Primary 605 Care: Findings from the DynAlRx study. medRxiv. 2024: 2024.04.18.24303004. Available 606 from: doi: 10.1101/2024.04.18.24303004.

	QOF	Register (annual	contract requirem	ents)
	SMI	Dementia	Depression	No register
Patients taking	Schizophrenia;	Vascular	Moderate	Generalised
APM with	Bipolar	dementia;	depressive	anxiety
typical	disorder;	Alzheimer's	disorder	disorder;
diagnoses	Psychotic	disease		Autism
	depression			
Registration	Yes	Yes	Yes	No
GP review	Yes	Yes	Yes	No
Blood pressure	Yes	No	No	No
BMI	Yes	No	No	No
Lipids	Yes	No	No	No
HBA1c /glucose	Yes	Yes	No	No
Alcohol	Yes	No	No	No
consumption				

Table S1: Typical QOF register contractual requirements in the Primary Care GP Contract.These contractual requirements varied from UK nation to nation over the study period. The table shows the typical monitoring that a patient with a diagnosis would experience according to each register.

Antipsychotic	Read code (5-digit)	Count (2011)	Relative proportion (%) (2011)	Count (2020)	Relative Proportion (%) (2020)	First or Second Generation		Licensed indica	ation in UK British Nat	ional Formulary (2024)		
							Psychosis/agitation in Serious Mental Illness (Schizophrenia, Bipolar Disorder, Psychotic Depression)	Psychosis in Parkinson's Disease	Management of Behavioural and Psychological Symptoms in Dementia	Depression (adjunctive treatment, psychosis not required)	Anxiety	Control of deviant antisocial sexual behaviour	Non- psychiatric uses (e.g. nausea)
Quetiapine	d4s	6362	28.0	12338	37.1	2	YES	NO	NO	YES	NO	NO	NO
Olanzapine	d4r OR d58	5430	23.9	7527	22.6	2	YES	NO	NO	NO	NO	NO	NO
Risperidone	d4p	3377	14.8	5106	15.3	2	YES	NO	NO	NO	NO	NO	NO
Amisulpride	d4t	1531	6.7	1190	3.6	2	YES	NO	NO	NO	NO	NO	NO
Aripiprazole	d4v	1381	6.1	4303	12.9	2	YES	NO	NO	NO	NO	NO	NO
Haloperidol	d47 OR d55	997	4.4	825	2.5	1	YES	NO	YES	NO	NO	NO	YES
Chlorpromazine	d41	971	4.3	633	1.9	1	YES	NO	NO	NO	YES	NO	YES
Trifluoperazine	d4h	669	2.9	117	0.4	1	YES	NO	NO	NO	YES	NO	YES
Pericyazine	d4a	576	2.5	176	0.5	1	YES	NO	NO	NO	YES	NO	NO
Promazine	d4e	508	2.2	244	0.7	1	YES	NO	NO	NO	NO	NO	YES
Sulpride	d4f	490	2.2	271	0.8	1	YES	NO	NO	NO	NO	NO	NO
Zuclopenthixol	d4j OR d57	211	0.9	257	0.8	1	YES	NO	NO	NO	NO	NO	NO
Flupentixol	d51	159	0.7	104	0.3	1	YES	NO	NO	YES	NO	NO	NO
Benperidol	d42	39	0.2	34	0.1	1	NO	NO	NO	NO	NO	YES	NO
Pimozide	d4c	23	0.1	10	0.0	1	YES	NO	NO	NO	NO	NO	NO
Clozapine	d4l	14	0.1	8	0.0	2	YES	YES	NO	NO	NO	NO	NO
Paliperidone	d4w	<5	0.0	14	0.0	2	YES	NO	NO	NO	NO	NO	NO
Asenapine	d4x	<5	0.0	<5	0.0	2	YES	NO	NO	NO	NO	NO	NO
Cariprazine	not listed in d4	<5	0.0	<5	0.0	2	YES	NO	NO	NO	NO	NO	NO
Lurasidone	d4y	<5	0.0	<5	0.0	2	YES	NO	NO	NO	NO	NO	NO
Droperidol	d44	<5	0.0	<5	0.0	1	NO	NO	NO	NO	NO	NO	YES

Loxapine	d4k	<5	0.0	<5	0.0	1	YES	NO	NO	NO	NO	NO	NO
Zuclopenthixol acetate	d4n	<5	0.0	<5	0.0	1	YES	NO	NO	NO	NO	NO	NO
Prochlorperazine as antipsychotic (excluded from 'total APM count as not used as an antipsychotic in UK)*	D4d (Dhe Antiemetic code use is not captured under d4 code)	<5	N/A	<5	N/A	N/A	YES	NO	NO	NO	YES	NO	YES
Levomepromazine (excluded from 'total APM count as not used as an antipsychotic in UK)*	d48	68	N/A	158	N/A	N/A	YES	NO	NO	NO	NO	NO	YES
Total (individual APM counts)		22773	100.1	33187	99.7	N/A							
Total (top 6 APM used in 2020)		19078	83.9	31289	94.0	N/A							
Total 1 st Generation APM		4658	20.5	2686	8.1	N/A							
Total 2 nd Generation APM		18115	79.7	30501	91.7	N/A							
"ALL APM Total"	codes d4 and d5 excluding any prochlorperazine antiemetic codes (dhe) and levomepromazine codes (22119	N/A	32086	N/A	N/A							
All APM total as a % of summation of individual APM count		97.1	N/A	96.7	N/A	N/A							







Figure S1: Prevalence of long-term APM use between 2011 and 2020










Figure S2: Proportions of patients taking long-term APM who have had psychiatric review in previous 12 months




Figure S3: Proportions of patients in 2020 prescribed -long APM who have had psychiatric review in the preceding time period of up to 5 years

All APM


Quetiapine


Olanzapine Risperidone

Amisulpride


Aripiprazole


- Haloperidol






Year










Figure S5: Proportion of total APM prescribed to patients on each QOF register